Evidence map›Paper›PMID 27088019›Full record

ArticleCase reports in dentistry2016

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

Andrea Cassoni, Umberto Romeo, Valentina Terenzi, Marco Della Monaca, Oriana Rajabtork Zadeh, Ingrid Raponi, Maria Teresa Fadda, Antonella Polimeni, Valentino Valentini

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in dentistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Andrea CassoniOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Umberto RomeoOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Valentina TerenziOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Marco Della MonacaOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Oriana Rajabtork ZadehOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Ingrid RaponiOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Maria Teresa FaddaOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Antonella PolimeniOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Valentino ValentiniOdontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective. The acronym MRONJ has been created in order to identify "Medication-Related Osteonecrosis of the Jaw," observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron's disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case. On August, 2014, a 63-year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from 2010 to 2013 presented referring pain in the right mandible. Results. This patient presented with nonexposed osteonecrosis of the jaw after placement, on September, 2010, of four titanium fixtures in the mandible. Conclusions. The authors suggest that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.

Identifiers

PMID27088019
PMCPMC4819088
OpenAlexW2299660974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.